Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70134 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Maria Eugenia Alvaro und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Onco-Hematology, AO of Cosenza, Hematology Unit, Cosenza, Italy. Hauptthemen laut MEDLINE: Ikaros Transcription Factor, Multiple Myeloma, Ubiquitin-Protein Ligases, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Multiple myeloma (MM) remains an incurable plasma cell malignancy characterized by recurrent relapses and eventual refractoriness to standard agents, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti‐CD38 monoclonal antibodies. With frontline therapeutic strategies increasingly employing quadruplet induction regimens and prolonged lenalidomide maintenance, resistance to traditional IMiDs has become more prevalent, creating an urgent need for next‐generation cereblon E3 ligase modulators (CELMoDs) capable of overcoming IMiD refractoriness and enhancing the immunologic microenvironment. Iberdomide (CC‐220) and mezigdomide (CC‐92480) are rationally engineered CELMoDs designed to achieve deeper degradation of Ikaros (IKZF1) and Aiolos (IKZF3), restore cereblon‐mediated activity, and potentiate immune effector responses. This review explores the core biological features of these agents, detailing their mechanisms of action, preclinical and clinical activity, as well as safety profile. We examine how their pharmacodynamic properties differ from classical IMiDs, their relevance in triple‐class and penta‐refractory MM, and their integration into emerging combination strategies with monoclonal antibodies and T‐cell–redirecting immunotherapies. Special emphasis is placed on ongoing and future trials that may refine their therapeutic positioning, alongside a critical appraisal of the limitations and future directions of this rapidly advancing drug class.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Onco-Hematology, AO of Cosenza, Hematology Unit, Cosenza, Italy.
- Emergency and Internal Medicine Department, Saint Joseph Hospital, East Jerusalem, Palestine.
- Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.
- AIL Sezione di Cosenza, Cosenza, Italy.
- Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.
ORCID-Profile: Francesco Mendicino, Massimo Gentile
Zitieren
APA
Alvaro, M. E., Martino, E. A., Caserta, S., Skafi, M., Bruzzese, A., Amodio, N., Lucia, E., Olivito, V., Labanca, C., Mendicino, F., Vigna, E., Morabito, F., & Gentile, M. (2026). Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM. European Journal of Haematology. https://doi.org/10.1111/ejh.70134
Vancouver
Alvaro ME, Martino EA, Caserta S, Skafi M, Bruzzese A, Amodio N, et al. Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM. European Journal of Haematology. 2026. doi:10.1111/ejh.70134
BibTeX
@article{Alvaro2026,
author = {Alvaro, Maria Eugenia and Martino, Enrica Antonia and Caserta, Santino and Skafi, Mamdouh and Bruzzese, Antonella and Amodio, Nicola and Lucia, Eugenio and Olivito, Virginia and Labanca, Caterina and Mendicino, Francesco and Vigna, Ernesto and Morabito, Fortunato and Gentile, Massimo},
title = {Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70134}
}
EUVIMED